Aureka raises $100M Series B for AI drug discovery; Isomorphic Labs reportedly secures $2.1 billion
Aureka closed a $100 million Series B round to scale its AI-based drug discovery. According to one report, DeepMind's Isomorphic Labs secured $2.1 billion for AI drug discovery (Aug. 10–11).
Who is affected and how
- pharmaceuticals
- Capital flowing to AI-native biotechs increases partnership and competitive pressure.
- medtech company
- Funding dynamics in AI drug discovery also affect the supplier ecosystem.
Sources
- Aureka lands $100M series B to scale AI drug discoveryfirstword pharma · Aug 11, 2026
- Aureka Open-Sourced Antibody AI That Beats AlphaFold 3; Closes $100M Drug Discovery Roundtech times · Aug 11, 2026
- Aureka raises $100M Series B to challenge AlphaFold in AI-driven drug discoveryaistartupsnews.com · Aug 11, 2026
- DeepMind's Isomorphic Labs Secures $2.1 Billion for AI Drug Discovery · Gramintograminto.com · Aug 10, 2026
- How Isomorphic Labs is rethinking drug discovery as a compute problem - OpenHiveopen-hive.com · Aug 13, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.